Neogen (NEOG) Q1 2025 earnings summary

Executive summary

• Q1 FY25 revenue was $217.0 million, down 5.3% year-over-year, with core revenue declining 1.4% excluding FX and discontinued lines; Food Safety core growth was 1.1% while Animal Safety and Genomics faced headwinds.

• Net loss was $12.6 million ($-0.06 per diluted share), compared to net income of $1.5 million ($0.01) in the prior year, reflecting lower sales, higher operating expenses, and increased integration costs.

• Adjusted Net Income was $14.4 million ($0.07 per diluted share), down from $23.7 million ($0.11) year-over-year.

• Integration of the 3M Food Safety business progressed, with system and ERP-related shipping challenges resolved and focus shifting to growth and portfolio review.

• Margins were pressured by lower volumes, higher shipping/distribution costs, and integration expenses, but targeted actions and margin protection initiatives are underway.

Financial highlights

• Q1 revenue was $217.0 million, down from $228.99 million year-over-year; core revenue declined 1% year-over-year, with a 390 basis point FX headwind.

• Adjusted EBITDA was $43.7 million (20.1% margin), down from $52.4 million (22.9%) last year.

• Net loss was $12.6 million, or $(0.06) per share, versus net income of $1.5 million, or $0.01 per share, prior year.

• Gross margin was 48.4%, down from 51.0% year-over-year; adjusted gross margin was 50.7% versus 51.6%.

• Cash and cash equivalents at quarter-end were $120.5 million; non-current debt stood at $900.0 million.

Outlook and guidance

• Full-year FY25 revenue guidance maintained at $925–$955 million, with Adjusted EBITDA guidance of $215–$235 million and mid-single-digit core revenue growth expected.

• CapEx for FY25 expected at $85 million, with $55 million related to 3M Food Safety integration and new manufacturing facility, front-loaded in H1.

• Management expects continued impact from global economic headwinds, higher interest rates, and geopolitical tensions throughout fiscal 2025.

• Margin improvement anticipated for the rest of the year, driven by higher revenue, gross margin gains, and operating expense efficiency.

• Free cash flow for the year expected to be positive, with CapEx peaking in Q1 and Q2.